Abstract
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Coronaviruses
Title:Favipiravir in the Spotlight: In Search of Treatment Against COVID-19
Volume: 2 Issue: 1
Author(s): Victor Facchinetti and Marcus Vinícius Nora de Souza*
Affiliation:
- Fundacao Oswaldo Cruz, Instituto de Tecnologia em Farmacos, Rua Sizenando Nabuco 100, Rio de Janeiro, RJ,Brazil
Keywords: Coronavirus, COVID-19, favipiravir, synthesis, mechanism of action, pharmacology
Abstract:
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), sometimes referred to as the novel coronavirus (2019-nCoV), is currently a worldwide threat to public health. According to the Johns Hopkins University monitor (available at, coronavirus.jhu.edu/map), there have been more than 10 million reported cases of coronavirus 2019 disease (COVID-19) and 500,000 deaths as of June 29, 2020, deeming urgent the identification of a drug candidate and treatment regimen.
Objective: This work aims to compile the current knowledge available on this drug, including its background, approved uses, some synthetic methods, the primary pharmacological aspects, the results against COVID-19 reported so far, and ongoing clinical trials against COVID-19.
Methods: We reviewed relevant press releases, scientific articles, and official documents to compile information about Favipiravir.
Results: We highlight, in a clear and concise form, not only the published and ongoing clinical trials on the use of Favipiravir against COVID-19 but also compile some relevant synthetic and pharmacological information available about this drug.
Conclusion: The Antiviral Favipiravir has shown interesting preliminary results, but it seems too early to recommend a treatment protocol for COVID-19 based on this drug. Robust clinical trials that will provide less biased data on its efficacy and safety are being pushed forward by FUJIFILM Corporation and by research groups around the globe.
Export Options
About this article
Cite this article as:
Facchinetti Victor and de Souza Marcus Vinícius Nora*, Favipiravir in the Spotlight: In Search of Treatment Against COVID-19, Coronaviruses 2021; 2 (1) : e160223184322 . https://dx.doi.org/10.2174/2666796701999200729155347
DOI https://dx.doi.org/10.2174/2666796701999200729155347 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mathematical Descriptors for the Prediction of Property, Bioactivity, and Toxicity of Chemicals from their Structure: A Chemical-Cum-Biochemical Approach
Current Computer-Aided Drug Design COVID-19: Potential Repurposing Drugs
Infectious Disorders - Drug Targets Maternal Sepsis 2010: Early Recognition and Aggressive Treatment with Early Goal Directed Therapy can Improve Maternal Outcomes
Current Women`s Health Reviews Assessing the Effectiveness of a Telemedicine Initiative in Clinical Management of Children Living with HIV/AIDS in Maharashtra, India
Current HIV Research Virtual High Throughput Screening to find Suitable Inhibitors for SARSCoV- 2 Main Protease
Anti-Infective Agents Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An <i>In Silico</i> Study
Medicinal Chemistry Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews High Throughput Screening for Bioactive Components from Traditional Chinese Medicine
Combinatorial Chemistry & High Throughput Screening Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Evaluation and Comparison of the Ability of Online Available Prediction Programs to Predict True Linear B-cell Epitopes
Protein & Peptide Letters Clinical Evidence and Therapeutic Treatments at the Time of the Coronaviruses Responsible for SARS: A Perspective and Points of view with a Focus on Vascular Endothelium
Coronaviruses Docking Simulations Exhibit Bortezomib and other Boron-containing Peptidomimetics as Potential Inhibitors of SARS-CoV-2 Main Protease
Current Chemical Biology Alterations in Clinical Characteristics of Blood Donors Post COVID-19 Recovery
Current Pharmaceutical Design Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies
Mini-Reviews in Medicinal Chemistry Role of Cations in the Interaction of Pradimicins with HIV-1 Envelope gp120
Current Topics in Medicinal Chemistry COVID-19: Innovative Antiviral Drugs Required for Long-Term Prevention and Control of Coronavirus Diseases
Current Medicinal Chemistry Mass Spectrometry, Proteomics, Data Mining Strategies and Their Applications in Infectious Disease Research.
Anti-Infective Agents in Medicinal Chemistry COVID-19 Effect: Time to Change the Way of Research
Coronaviruses Important Role of Relaxation Techniques in Immune Functions, Glycemic Control, and Stress in Diabetic Patients with COVID-19: A Review
Current Diabetes Reviews Non-Pharmaceutical Interventions are Measures to Control Coronavirus Disease-2019 (COVID-19) Transmission in India
Coronaviruses